Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sibeprenlimab in IgA Nephropathy
NCT06740526Phase 2Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of sibeprenlimab in IgA nephropathy (IgAN), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Dec 2024; status: active, not recruiting.
02
Drugs
sibeprenlimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06740526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740526.